Evidence map›Paper›PMID 39518315›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Primary Large-Cell Neuroendocrine Carcinoma of the Breast.

Bicheng Zhang, Fengbo Huang, Siyu Guo, Dang Wu, Xiaofang Xiao, Ting Zhang

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bicheng ZhangDepartment of Radiation Oncology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China.ORCID 0000-0002-6002-8000
Fengbo HuangDepartment of Pathology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China.
Siyu GuoDepartment of Radiation Oncology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China.
Dang WuDepartment of Radiation Oncology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China.
Xiaofang XiaoDepartment of Medical Oncology, The Fourth Affiliated Hospital of Zhejiang University, School of Medicine, Yiwu 322000, China.
Ting ZhangDepartment of Radiation Oncology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China.ORCID 0000-0002-2044-2610

Funding

National Natural Science Foundation of China 82073142, DWNational Natural Science Foundation of China 82173089, TZ
6 · The paper itself

Abstract

Breast neuroendocrine carcinoma (NECB) is a rare type of breast tumor. Large-cell neuroendocrine carcinomas of the breast (LCNECB) are a special and rare histological subtype of NECB. Here, we present a case of a 59-year-old woman who was diagnosed with an LCNECB. A mass in the upper outer quadrant of the right breast was revealed via imaging. A histological examination showed the tumor cells were composed of clusters of large cells with obvious atypia that were polygonal or irregularly shaped. The patient underwent a right-breast-conserving radical surgery and sentinel lymph node biopsy (SLB). A histopathological examination revealed that the tumor of the right breast was 2.5 × 2 cm in size with vascular invasion, and the sentinel lymph node was negative. The immunohistochemical results showed that the tumor cells were diffuse and positive for chromogranin A (CgA), synaptophysin (Syn), and INSM1. The patient successfully completed chemotherapy and radiotherapy and is currently undergoing endocrine therapy.

Indexed as

breast neuroendocrine carcinomaCgAINSM1large-cell neuroendocrine carcinomasSyn

Identifiers

PMID39518315
PMCPMC11544942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.